First-in-human phase I study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of PF-07209960 in patients with advanced or metastatic solid tumors

By sjmartinez • February 19, 2025

Naing A, McKean M, Rosen LS, Sommerhalder D, Shaik NM, Wang IM, Le Corre C, Kern KA, Mishra NH, Pal SK. First-in-human phase I study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of PF-07209960 in patients with advanced or metastatic solid tumors. ESMO Open. 2025 Feb 17;10(3):104291. doi: 10.1016/j.esmoop.2025.104291. Epub ahead of print. PMID: 39965362.

Tags: advanced or metastatic solid tumors, anti-drug antibodies, anti-PD-1–IL-15 fusion, antibody–cytokine fusion molecule, Hematology/Oncology, phase I study, Publications

Real-World Toxicity and Efficacy Profile of Enfortumab Vedotin With or Without Pembrolizumab in Ultra-Elderly Patients With Advanced Urothelial Carcinoma

Mar N, Cabral MY, Go J, Kaakour D, Dwabe S, Seyedin SN, Drakaki A. Real-World Toxicity and Efficacy Profile of Enfortumab Vedotin With or Without[...]

A Case of Gastrointestinal Krukenberg Tumor Initially Suspected as Primary Ovarian Cancer and the Implications for Management

Sidhu N, Le BM, Doan EL, Dao KT, Montana W. A Case of Gastrointestinal Krukenberg Tumor Initially Suspected as Primary Ovarian Cancer and the Implications[...]

Choreiform Movements and Pachymeningeal Enhancement in an Elderly Patient With Abnormal Blood Counts: A Case Report and Review of Literature

Bondariyan N, Patel M, Shah P, Park D, Dermarderosian A, Arfaie S, Mashayekhi M, Dashtipour K, Akhtari M. Choreiform Movements and Pachymeningeal Enhancement in an[...]